Lupin launches Mirabegron Extended-Release tablets

22 Apr 2024 Evaluate

Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the U.S. (IQVIA MAT February 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

1663.00 15.25 (0.93%)
03-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1508.40
Dr. Reddys Lab 6332.85
Cipla 1424.40
Zydus Lifesciences 992.00
Lupin 1663.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.